Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Bioregenx (BRGX) Net Cash Flow (2022 - 2025)

Bioregenx's Net Cash Flow history spans 4 years, with the latest figure at $22436.0 for Q4 2025.

  • Quarterly results put Net Cash Flow at $22436.0 for Q4 2025, up 243.33% from a year ago — trailing twelve months through Dec 2025 was $13013.0 (up 118.6% YoY), and the annual figure for FY2025 was $13013.0, up 118.6%.
  • Net Cash Flow for Q4 2025 was $22436.0 at Bioregenx, up from -$6731.0 in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $68381.0 in Q4 2023 to a low of -$239056.0 in Q2 2023.
  • The 4-year median for Net Cash Flow is -$9508.0 (2024), against an average of -$36920.4.
  • Peak annual rise in Net Cash Flow hit 8005.32% in 2023, while the deepest fall reached 28655.33% in 2023.
  • Year by year, Net Cash Flow stood at -$865.0 in 2022, then skyrocketed by 8005.32% to $68381.0 in 2023, then plummeted by 122.89% to -$15653.0 in 2024, then soared by 243.33% to $22436.0 in 2025.
  • According to Business Quant data, Net Cash Flow over the past three periods came in at $22436.0, -$6731.0, and -$29972.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.